Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases.

Epithelioid trophoblastic tumor choriocarcinoma testicular germ cell tumor trophoblastic tumor β-human chorionic gonadotrophin

Journal

Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547

Informations de publication

Date de publication:
24 Oct 2024
Historique:
received: 11 08 2024
revised: 12 10 2024
accepted: 23 10 2024
medline: 27 10 2024
pubmed: 27 10 2024
entrez: 26 10 2024
Statut: aheadofprint

Résumé

Epithelioid trophoblastic tumor (ETT) is an extremely rare chorionic-type neoplasm in the testis, with only seven cases reported in the literature. Here, we report five cases of testicular ETT from a single institution, constituting the largest series of this rare tumor to date. The patients had a mean age of 44 years (range, 20-68 years). Four patients had a previous history of testicular germ cell tumor (GCT) treated with chemotherapy, and they developed ETT in metastatic sites in a mean of 11 years (range, 3-15 years) after the initial diagnosis of testicular GCT. Only one patient had ETT in the testis. Three patients had a normal serum beta-human chorionic gonadotropin (β-hCG) level, and two patients had a level that was slightly elevated, but far below that typically seen in patients with choriocarcinoma. ETT was characterized by a proliferation of intermediate trophoblastic cells with abundant eosinophilic cytoplasm, and the tumors frequently had coagulative necrosis with eosinophilic debris, mimicking keratinizing squamous cell carcinoma. The trophoblastic phenotype of ETT was supported by its immunoreactivity for trophoblastic markers, including GATA-3 (3 of 3 cases tested), α-inhibin (3/4), p63 (3/5), and β-hCG (3/4). ETT was also positive for cytokeratin (4/4) and GCT marker SALL4 (3/3). Despite surgery and chemotherapy, two patients died of disease 17 months after ETT diagnosis, and three patients were alive with metastatic disease at a mean of 20 months (range, 15-28 months). Our results demonstrate that ETT may be an aggressive disease associated with distinct pathologic features and poor clinical outcome.

Identifiants

pubmed: 39461379
pii: S0046-8177(24)00182-5
doi: 10.1016/j.humpath.2024.105673
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105673

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest All authors declare they have no conflict of interest.

Auteurs

Georges C Tabet (GC)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Lan Zheng (L)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Hossein Hosseini (H)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

John Ward (J)

Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Louis Pisters (L)

Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Matthew T Campbell (MT)

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Shi-Ming Tu (SM)

Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

Bogdan Czerniak (B)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Charles C Guo (CC)

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: ccguo@mdanderson.org.

Classifications MeSH